Historical Valuation
Virax Biolabs Group Ltd (VRAX) is now in the Fair zone, suggesting that its current forward PS ratio of 62.82 is considered Fairly compared with the five-year average of -3.16. The fair price of Virax Biolabs Group Ltd (VRAX) is between 0.10 to 0.65 according to relative valuation methord.
Relative Value
Fair Zone
0.10-0.65
Current Price：0.36
Fair
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
Virax Biolabs Group Ltd (VRAX) has a current Price-to-Book (P/B) ratio of 0.47. Compared to its 3-year average P/B ratio of 0.77 , the current P/B ratio is approximately -38.69% higher. Relative to its 5-year average P/B ratio of 1.99, the current P/B ratio is about -76.22% higher. Virax Biolabs Group Ltd (VRAX) has a Forward Free Cash Flow (FCF) yield of approximately -234.91%. Compared to its 3-year average FCF yield of -152.89%, the current FCF yield is approximately 53.65% lower. Relative to its 5-year average FCF yield of -133.54% , the current FCF yield is about 75.92% lower.
P/B
Median3y
0.77
Median5y
1.99
FCF Yield
Median3y
-152.89
Median5y
-133.54
Competitors Valuation Multiple
AI Analysis for VRAX
The average P/S ratio for VRAX competitors is 10.60, providing a benchmark for relative valuation. Virax Biolabs Group Ltd Corp (VRAX.O) exhibits a P/S ratio of 62.82, which is 492.49% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
Performance Decomposition
AI Analysis for VRAX
1Y
3Y
5Y
Market capitalization of VRAX increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of VRAX in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is VRAX currently overvalued or undervalued?
Virax Biolabs Group Ltd (VRAX) is now in the Fair zone, suggesting that its current forward PS ratio of 62.82 is considered Fairly compared with the five-year average of -3.16. The fair price of Virax Biolabs Group Ltd (VRAX) is between 0.10 to 0.65 according to relative valuation methord.
What is Virax Biolabs Group Ltd (VRAX) fair value?
VRAX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Virax Biolabs Group Ltd (VRAX) is between 0.10 to 0.65 according to relative valuation methord.
How does VRAX's valuation metrics compare to the industry average?
The average P/S ratio for VRAX's competitors is 10.60, providing a benchmark for relative valuation. Virax Biolabs Group Ltd Corp (VRAX) exhibits a P/S ratio of 62.82, which is 492.49% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
What is the current P/B ratio for Virax Biolabs Group Ltd (VRAX) as of Jan 10 2026?
As of Jan 10 2026, Virax Biolabs Group Ltd (VRAX) has a P/B ratio of 0.47. This indicates that the market values VRAX at 0.47 times its book value.
What is the current FCF Yield for Virax Biolabs Group Ltd (VRAX) as of Jan 10 2026?
As of Jan 10 2026, Virax Biolabs Group Ltd (VRAX) has a FCF Yield of -234.91%. This means that for every dollar of Virax Biolabs Group Ltd’s market capitalization, the company generates -234.91 cents in free cash flow.
What is the current Forward P/E ratio for Virax Biolabs Group Ltd (VRAX) as of Jan 10 2026?
As of Jan 10 2026, Virax Biolabs Group Ltd (VRAX) has a Forward P/E ratio of -0.38. This means the market is willing to pay $-0.38 for every dollar of Virax Biolabs Group Ltd’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Virax Biolabs Group Ltd (VRAX) as of Jan 10 2026?
As of Jan 10 2026, Virax Biolabs Group Ltd (VRAX) has a Forward P/S ratio of 62.82. This means the market is valuing VRAX at $62.82 for every dollar of expected revenue over the next 12 months.